You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 30, 2026

List of Excipients in API DOXORUBICIN HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing DOXORUBICIN HYDROCHLORIDE

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc DOXORUBICIN HYDROCHLORIDE doxorubicin hydrochloride 0069-3030 HYDROCHLORIC ACID
Pfizer Laboratories Div Pfizer Inc DOXORUBICIN HYDROCHLORIDE doxorubicin hydrochloride 0069-3030 SODIUM CHLORIDE
Pfizer Laboratories Div Pfizer Inc DOXORUBICIN HYDROCHLORIDE doxorubicin hydrochloride 0069-3030 WATER
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Get Started Free

Detailed excipient profiles for DOXORUBICIN HYDROCHLORIDE

Excipient focus: AMMONIUM SULFATE

Excipient focus: CHOLESTEROL

Excipient focus: HISTIDINE

Excipient focus: HYDROCHLORIC ACID

Excipient focus: HYDROGENATED SOYBEAN LECITHIN

Excipient focus: LACTOSE MONOHYDRATE

Excipient focus: N-(CARBONYL-METHOXYPOLYETHYLENE GLYCOL 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE

Excipient focus: N-(CARBONYL-METHOXYPOLYETHYLENE GLYCOL 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE, SODIUM SALT

Excipient focus: SODIUM CHLORIDE

Excipient focus: SODIUM HYDROXIDE

Excipient focus: SODIUM N-(CARBONYL-METHOXYPOLYETHYLENE GLYCOL 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE

Excipient focus: SUCROSE

Excipient focus: WATER

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links